Literature DB >> 32143932

Drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat.

Erik A Jensen1, Robin S Roberts2, Barbara Schmidt3.   

Abstract

Infants born very preterm have a variable baseline risk of bronchopulmonary dysplasia (BPD). Using the example of evidence-based drug therapies to prevent BPD, we designed a visual aid that displays the "number needed to treat" with CIs for caffeine, vitamin A, and hydrocortisone over a range of baseline risks.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NNT; baseline risk; caffeine; chronic lung disease; evidence-based medicine; hydrocortisone; vitamin A

Year:  2020        PMID： 32143932     DOI： 10.1016/j.jpeds.2020.01.070

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  5 in total

1.  Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.

Authors:  Matthew A Rysavy; Lei Li; Jon E Tyson; Erik A Jensen; Abhik Das; Namasivayam Ambalavanan; Matthew M Laughon; Rachel G Greenberg; Ravi M Patel; Claudia Pedroza; Edward F Bell
Journal:  J Pediatr       Date:  2021-05-15       Impact factor: 6.314

2.  Vitamin A supplementation prevents the bronchopulmonary dysplasia in premature infants: A systematic review and meta-analysis.

Authors:  Yueqin Ding; Zhifeng Chen; Yanling Lu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

3.  The effects of early vitamin A supplementation on the prevention and treatment of bronchopulmonary dysplasia in premature infants: a systematic review and meta-analysis.

Authors:  Li Huang; Diqing Zhu; Gaofeng Pang
Journal:  Transl Pediatr       Date:  2021-12

Review 4.  Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia.

Authors:  Yufeng Xi; Rong Ju; Yujia Wang
Journal:  Front Pediatr       Date:  2022-04-04       Impact factor: 3.569

Review 5.  Dose-Related Adverse Drug Events in Neonates: Recognition and Assessment.

Authors:  Karel Allegaert; John van den Anker
Journal:  J Clin Pharmacol       Date:  2021-06       Impact factor: 3.126
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.